LEXINGTON, Mass. & BRISTOL, Conn.--(BUSINESS WIRE)--Leading into Breast Cancer Awareness Month, FUJIFILM Healthcare Americas Corporation, a leading provider of medical imaging and informatics solutions, and Beekley Medical®, a leading supplier of niche medical products, hosted its second annual Breast Imaging Education Summit at Fujifilm's Valhalla, NY headquarters on September 20-21. The complimentary event was well attended and convened radiologic technologists specializing in breast imaging. ...

Core Insights - Perimeter Medical Imaging AI, Inc. will present a business update at the Small Cap Growth Virtual Investor Conference on October 16, 2025 [1][2] Company Overview - Perimeter Medical Imaging AI is a commercial-stage medical technology company based in Toronto, Canada, and Dallas, Texas, focused on transforming cancer surgery with advanced imaging tools [3] - The company offers the FDA-cleared Perimeter S-Series OCT system, which provides real-time, cross-sectional visualization of excised tissues at the cellular level [3] - The investigational Perimeter B-Series OCT, featuring ImgAssist AI, is currently under evaluation in a pivotal clinical trial, supported by a grant of up to US$7.4 million from the Cancer Prevention and Research Institute of Texas [3] Product Information - The Perimeter B-Series OCT is not available for sale in the United States, while the Perimeter S-Series OCT has 510(k) clearance under a general indication [4]

Core Insights - GE HealthCare (GEHC) has announced a strategic collaboration with Erasmus MC University Medical Center to evaluate next-generation total body PET/CT technology, aiming to enhance precision imaging and cancer care [1][8] - The partnership focuses on early disease detection, personalized treatment planning, and outcome monitoring through advanced imaging capabilities and AI-driven innovations [1][2] Company Developments - The collaboration is expected to accelerate breakthroughs in oncology and theranostics, improving the speed, clarity, and confidence in disease detection, staging, and treatment [2][4] - GEHC's market position in the molecular imaging segment is likely to strengthen, showcasing the clinical potential of its next-generation PET/CT technology [4][10] - The partnership will explore protocol optimization, dose reduction, and dynamic imaging capabilities, which can help accelerate regulatory approvals and drive adoption among hospitals [11][12] Financial Performance - GEHC currently has a market capitalization of $34.3 billion and an earnings yield of 6.03%, significantly higher than the industry's 0.09% [5] - In the last reported quarter, GEHC delivered an earnings surprise of 16.5% [5] Industry Outlook - The global cancer diagnostics market is projected to grow from $109.61 billion in 2024 to $155.07 billion by 2030, with a CAGR of 6.14% from 2025 to 2030, driven by the increasing prevalence of cancer and advancements in diagnostic technologies [13]

Core Insights - Royal Philips has achieved a significant milestone with the installation of its 5,000th Zenition mobile surgery imaging system, highlighting its global impact in healthcare with over 15 million patients treated annually in more than 170 countries [1][4]. Company Overview - Philips is a leading health technology company focused on improving health and well-being through innovation, generating EUR 18 billion in sales in 2024 and employing approximately 67,300 people globally [10]. Product Innovation - The Zenition mobile C-arm platform is designed to enhance workflow efficiency and deliver high-quality imaging, addressing challenges such as staff shortages and budget constraints in hospitals and surgical centers [2][5]. - The platform incorporates advanced features like Position Memory and BodySmart software, which reduce the need for C-arm repositioning by 45% [2][3]. Historical Context - The 5,000th installation coincides with the 70th anniversary of Philips' first mobile C-arm introduction in 1955, marking a legacy of continuous innovation in surgical imaging [3][5]. Market Reception - The Zenition platform is recognized for its ease of use, reliability, and clinical versatility, gaining endorsement from hospitals across various regions including Europe, North America, and emerging markets [6].

Core Insights - Butterfly Network has launched an AI-powered Gestational Age tool in Malawi and Uganda to enhance maternal and fetal health through improved access to ultrasound technology [1][4] - The tool allows lower-skilled healthcare workers to estimate gestational age quickly and accurately without requiring image interpretation or extensive training [4][5] - The initiative is part of Butterfly's broader commitment to advancing maternal health in under-resourced settings, supported by the Gates Foundation and developed in collaboration with the University of North Carolina [4][5] AI-Enabled Gestational Age Tool - The AI tool addresses the critical need for affordable ultrasound technology in low-resource settings, where 92% of maternal and neonatal mortality occurs in low- and middle-income countries [2] - It enables midwives and other healthcare providers to deliver timely care by determining the appropriate gestational age for necessary medical interventions [4] Milestone Achievements - Butterfly Network has successfully deployed 1,000 handheld ultrasound probes and trained over 1,050 healthcare providers in Sub-Saharan Africa from September 2022 to December 2024 [6] - As of July 2025, 1.8 million scans have been conducted, averaging 83,000 scans monthly, demonstrating significant integration of obstetrical ultrasound services in over 697 public health facilities [6] Positive Impact on Maternal Health - Preliminary data from Kenya indicates a significant increase in women seeking antenatal care before 24 weeks, with over 90% patient satisfaction reported [9] - In South Africa, there has been a notable reduction in stillbirths and maternal mortality, with 873 appropriate referrals made for higher-level care [10][11] - The average scan time for providers has been reduced to 1.3 minutes, with a high confidence level in detecting key maternal conditions post-training [12] Technological Advancements - The latest Butterfly device, iQ3, has been approved for use in South Africa and Kenya, enhancing the quality and accessibility of POCUS [7] - Butterfly's innovations have received multiple accolades, including the Best Medical Technology at the 2024 Prix Galien USA Awards, highlighting the company's commitment to advancing healthcare technology [14]

Core Insights - Positron Corporation has announced a partnership with MedAxiom to enhance the adoption of PET imaging technology in cardiovascular care [1][3][4] Company Overview - Positron Corporation specializes in the development, manufacturing, and sale of advanced PET and PET-CT imaging systems and clinical services for nuclear medicine healthcare providers in North America [5][6] - The company focuses on cardiac Positron Emission Tomography (PET) imaging, which is considered the gold standard in cardiac diagnostics [6][7] Partnership Details - The collaboration with MedAxiom connects Positron to leading cardiovascular organizations, providing access to valuable insights and exposure that can advance the adoption of PET technology [3][4] - MedAxiom is recognized for its extensive network and for driving innovation in cardiovascular medicine, which will benefit Positron in terms of market intelligence and clinical insights [2][3] Market Position and Technology - Positron's unique market position and innovative PET/PET-CT technologies are expected to facilitate the growth of the nuclear imaging market [7] - The company plans to introduce a state-of-the-art PET-CT 4D molecular imaging device, the Affinity PET-CT 4D 64-Slice, which will enhance the capabilities of nuclear cardiologists [7][8] Commitment to Advancement - Positron is dedicated to expanding the cardiac and oncology PET modalities by delivering high-quality technology and value to imaging specialists [8]

Core Insights - Positron Corporation has won the Innovation Award in the PET-CT Imaging category at the 2025 Medical Device Network Excellence Awards for its advancements in PET-CT imaging technology [1][2] - The company's PET-CT systems are recognized for enhancing accessibility, efficiency, and clinical versatility in healthcare [2] Affordability and Design - Positron has developed economically accessible PET-CT solutions that address the high costs and space requirements of traditional systems, making advanced imaging feasible for smaller clinics and community hospitals [3] - The PET-CT 64 Slice is highlighted as the most cost-effective system in the US, enabling broader adoption of hybrid imaging [3] - Flexible rental and service options further support affordability, allowing facilities with limited capital to implement PET-CT technology [4] Workflow Efficiency - Positron's PET-CT systems are designed to enhance operational efficiency, allowing facilities to perform up to 20 or more exams per day, significantly higher than standalone PET systems [5] - The integration of CT attenuation correction improves image quality and accelerates scan times, contributing to increased throughput [5] Clinical Versatility - The PET-CT systems support a wide range of clinical needs, including advanced cardiac, oncology, and neurology imaging, all within a single platform [6] - The systems are optimized for myocardial perfusion imaging, crucial for assessing coronary artery disease and microvascular dysfunction, while also providing high sensitivity for tumor detection and neurological evaluation [6] Ongoing Innovation - Positron is committed to continuous innovation, with the upcoming Affinity 4D PET-CT system expected to launch in Q4 2025, featuring LYSO crystal technology, AI-enhanced motion monitoring, and advanced dose reduction techniques [7] - This focus on product development ensures that Positron's systems remain aligned with evolving clinical requirements [7] Market Position - Positron Corporation specializes in state-of-the-art PET and PET-CT imaging systems, co-developing and manufacturing solutions for nuclear medicine healthcare providers across North America [9][10] - The company aims to expand the cardiac and oncology PET modality by delivering superior technology and value to imaging specialists [12]

Core Insights - GE HealthCare (GEHC) has signed an exclusive license agreement with Lantheus Holdings to develop and commercialize the PSMA-targeted PET imaging agent, piflufolastat F18, in Japan for prostate cancer diagnostics [1][2]. Deal Overview - GEHC will develop, manufacture, and commercialize piflufolastat F18 in Japan, paying an upfront fee, milestone payments, and royalties on sales post-commercialization [2]. - Lantheus will provide regulatory dossiers, manufacturing competencies, and technical support to facilitate GEHC's clinical development efforts in Japan [2][11]. - The agent is already approved in the U.S. and Europe under the trade names PYLARIFY and PYLCLARI, respectively, for imaging in prostate cancer [3]. Market Potential - Japan has the third-largest number of prostate cancer cases globally, following the U.S. and China, making it a significant market for piflufolastat F18 [6]. - The aging population and increasing screening initiatives in Japan create a strong demand for advanced diagnostic solutions [6]. Strategic Implications - This agreement enhances GEHC's pipeline of radiopharmaceuticals and strengthens its Pharmaceutical Diagnostics division [9][10]. - The partnership validates GEHC's acquisition of Nihon Medi-Physics, which adds manufacturing and R&D capabilities essential for advancing prostate cancer detection [11]. Financial Performance - GEHC's shares have declined by 8.6% year-to-date, contrasting with a 4.7% gain in the industry and a 13.7% increase in the S&P 500 [4].

Core Insights - Algernon Pharmaceuticals has signed a definitive equipment order and financing agreement with Catalyst MedTech for four FDA-cleared Oncovision CareMiBrain™ PET scanner systems, valued at over CAD $4 million, to be used in planned neuroimaging clinics [1][2] - The PET scanner represents approximately 80% of the capital costs required to open a neuroimaging clinic, making this transaction crucial for the company's neuroimaging initiative [2] - The clinics will focus on early-stage detection of Alzheimer's Disease and other neurological conditions, addressing a significant market need as nearly 80% of Americans want to know if they have Alzheimer's before symptoms appear [3][4] Financial and Market Opportunity - The global economic burden of Alzheimer's was estimated at US$1 trillion in 2019, projected to rise to US$10 trillion by 2050, creating a substantial market opportunity for brain-specific PET scans and Alzheimer's treatments [4] - Each Alzheimer's PET brain scan will cost approximately US$5,000, with coverage from private insurance, Medicare, and Medicaid [6] - The current number of full-body PET/CT scanners in the U.S. is insufficient to meet the demand for Alzheimer's diagnostics, as 45% of existing scanners are primarily used for cancer and cardiac imaging [5] Technological Advancements - The CareMiBrain™ system is a dedicated brain PET scanner that reduces radiation exposure by up to 25% compared to full-body PET/CT units, enhancing patient safety [8][11] - The system features advanced technology for clarity and quantification, and is designed for patient comfort with ergonomic features [10][16] - Catalyst MedTech will provide consulting services to Algernon, including guidance on regulatory compliance and billing for the clinics [12] Strategic Partnerships and Future Plans - Algernon will collaborate with neurologists, geriatricians, and other medical professionals to generate patient referrals for the new clinics [3] - The company plans to change its name to Algernon Health Inc. to better reflect its focus on Alzheimer's diagnostics and neuroimaging clinics across North America [13] - Further updates on the company's expansion and growth plans, including the location of its first U.S. flagship neuroimaging clinic, will be provided soon [13]

Core Viewpoint - Guerbet has appointed Mr. Jérôme Estampes as interim Chief Executive Officer, succeeding Mr. David Hale, who is leaving the company to pursue new projects [2][3]. Company Management Changes - Mr. Jérôme Estampes has been with Guerbet since 2019 as Chief Administrative and Financial Officer, where he has developed a strong understanding of the company's financial, operational, and commercial challenges [3]. - The Board of Directors has expressed gratitude to Mr. David Hale for his contributions since joining in February 2018, first as Chief Commercial Officer and then as CEO from January 1, 2020 [2][4]. Transition and Future Leadership - The Board supports Mr. Estampes and he will have the assistance of Guerbet's Executive Committee to ensure a smooth transition and to continue implementing transformation measures and the commercial strategy [4]. - The Nominations and Remuneration Committee has initiated the recruitment process for a permanent Chief Executive Officer [4]. Company Overview - Guerbet is a global leader in medical imaging, focusing on improving patient care through innovation, with nearly a century of expertise [6]. - The company offers a comprehensive portfolio of pharmaceutical products, medical devices, and AI-driven solutions for diagnostic and interventional imaging [6]. - Guerbet invests 10% of its annual revenue in research and development and reported €786 million in revenue in 2023 [6].